

ABSTRACT

This invention concerns UGT2B7 and its ability to glucuronidate various drugs, including epirubicin. It concerns methods and compositions for determining the level of UGT2B7 activity based on genetic composition, and consequently, allows dosing of UGT2B7-glucuronidated drugs to be improved or optimized based on a patient's level of predicted UGT2B7 activity. It further concerns methods of treatment in which UGT2B7 substrates are administered to patients as part of a treatment regimen.